Filing Flows › Jaguar Health (JAGX) › Q4 2024
Jaguar Health (JAGX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 31, 2025
Jaguar Health (JAGX) reported revenue of $3.5M for the fourth quarter 2024 (Q4 2024), +53% from a year earlier and +13% from the quarter before. Operating margin was -232.5%, net loss $10.2M (291.7% of revenue).
Jaguar Health, Q4 2024: revenue $3.5M (+53% year over year), operating margin -232.5%, net loss $10.2M, operating cash flow −$7.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.5M | +13% | +53% |
| Operating profit | −$8.2M | — | — |
| Net earnings | −$10.2M | — | — |
| Operating cash flow | −$7.8M | — | — |
What changed
Revenue was $3.5M in Q4 2024, up 53% year over year and up 13% from the previous quarter. Product was the largest line at 99% of revenue.
Operating costs exceeded revenue by $8.2M, an operating margin of -232.5%. Total costs grew 18% against revenue growth of 53%. The fastest-growing cost line was Sales & marketing (+77%). The quarter ended with a net loss of $10.2M, wider than the previous quarter's $10.0M loss. Minority interests bore $314K of it: to shareholders the quarter was a loss of $9.9M.
Operating cash flow was −$7.8M. Non-cash charges added back $478K of depreciation and amortization and $372K of share-based compensation. Working capital and other items added $1.6M.
Questions
What was Jaguar Health's revenue in the fourth quarter 2024?
Jaguar Health (JAGX) reported revenue of $3.5M for the fourth quarter 2024 (Q4 2024), +53% from a year earlier and +13% from the quarter before.
Was Jaguar Health profitable in the fourth quarter 2024?
Operating loss was $8.2M (-232.5% of revenue) and net loss $10.2M.
Source: Jaguar Health 10-K on SEC EDGAR.